不同剂量阿托伐他汀对心肌梗死兔内皮祖细胞水平的影响  

Effect of Atrovastatin on endothelial progenitor cells in rabbits with myocardial infarction

作　　者：刘少奎[1] 杨桂美[1] 王筱梅[1] 初楠[1] 洪军[1] 王翠荣[1] 穆鑫[1] 

机构地区：[1]大连大学附属中山医院心内科,辽宁大连116001

出　　处：《中国现代医学杂志》2009年第23期3572-3576,共5页China Journal of Modern Medicine

摘　　要：目的观察不同剂量阿托伐他汀对心肌梗死兔循环内皮祖细胞水平的影响。方法新西兰大白兔结扎左冠状动脉前降支制成急性心肌梗死模型后,随机分成生理盐水对照组和阿托伐他汀治疗组[5mg/(kg·d)或20mg/(kg·d)],通过灌胃给药8周后,采用密度梯度离心法从外周血分离单个核细胞,接种于添加了内皮细胞生长培养基-2促微血管添加剂(EGM-2MV single quots)的内皮细胞基础培养基-2(EBM-2)中,进行循环内皮祖细胞培养,1周后,贴壁细胞用激光共聚焦显微镜鉴定FITC标记的异凝集素(FITC-UEA)和Di1标记的乙酰化低密度脂蛋白(Di1-acLDL)双染色阳性细胞为正在分化的循环内皮祖细胞,在倒置荧光显微镜下记数。结果常规剂量的阿托伐他汀明显增加外周血循环内皮祖细胞的数量,为(321.44±30.27),比对照组(211.17±18.65)和大剂量组的(240.29±44.37)明显增多(P<0.05)。大剂量组比对照组略有增加,但差异无显著性(P>0.05)。结论常规剂量阿托伐他汀能增加心肌梗死后兔外周血循环内皮组细胞的数量,而且这种作用不依赖于他汀类药物的降脂作用。但是加大剂量并不能进一步增加内皮祖细胞的数量。【Objective】To investigate whether Atrovastatin dose-dependently affects endothelial progenitor cells （EPCS） numbers in rats with myocardial infarction.【Methods】Rabbits with myocardial infarction, induced by ligating left anterior descending artery, were randomized to be treated with saline or Atrovastatin [Atro, 5 mg/（kg·d）, or 20 mg/（kg·d）] by gavage for 8 weeks since the day of operation. Then, total mononuclear cells （MNCS） were isolated from peripheral blood by Ficoll density gradient centrifugation, and the cells were plated on EBM-2 coated culture dishes for one week. Cells double-stained by both FITC-labelled lecfin from ulex europeaus （FITC- UEA） and Dillabelled acetylated low-density lipoprotein （Dil-acLDL） were counted as EPCS. [ Results ] Atrovastatin at the dose of 5 mg/kg significantly increased EPCS numbers in peripheral blood, which was higher than control group and group of Atrovastatin 20 mg/kg. There were no statistical difference between control group and atrovastatin 20 mg/kg group. [Conclusion] Atrovastafin can dose-independently increase the EPCS numbers in peripheral blood in rabbits with myocardial infarction which is independent with it＇s lipid-lowering effect.

关 键 词：循环内皮祖细胞 阿托伐他汀 心肌梗死 

分 类 号：R-332[医药卫生] R541.4